Pappas Capital
Bridging the Early-Stage Funding Gap.
Business Model:
Revenue: $0
Employees: 0-0
Rankings
Industries / Tags:
Detailed Pappas Capital Information
Geographic Data
Address: 2520 Meridian Parkway
City: Durham
State: NC
Zip: 27713
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$286M
Social
Twitter
Linkedin
Crunchbase
Metrics
4,557,711Website Global Rank
2,053Website Monthly Traffic
Twitter Followers
Description
Pappas Capital invests exclusively in the life science sector – biotechnology, biopharmaceuticals, drug delivery, medical devices and related ventures – across the United States and Canada. They operate three lines of business: Pappas Ventures, their flagship venture arm; Specialized Fund Management, where we create and manage custom-tailored investment vehicles; and Translational Medicine, where we partner with research universities to accelerate the development of their scientific discoveries and inventions.
Contact Phone:
+19199983300
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 5/2017 | OrphoMed | Series A | 39M |
| 10/2018 | CuraSen Therapeutics | Series A | 54.5M |
| 10/2019 | Allievex | Series A | - |
| 6/2007 | Athersys | Venture Round | 0 |
| 11/2018 | Ribometrix | Series A | 30M |
| 9/2018 | 4D Molecular Therapeutics | Series B | 0 |
| 5/2019 | Reneo Pharmaceuticals | Series A | 50M |
| 7/2020 | BioAtla | Series D | 0 |
| 7/2020 | VelosBio | Series B | 137M |
| 2/2022 | Plexium | Series B | 0 |
| 3/2023 | Horizon Quantum Computing | Series A | 0 |
| 3/2001 | LiveWire Logic | Venture Round | 2.7M |
| 8/2022 | Aktis Oncology | Series A | 0 |
| 8/2017 | Amplyx Pharmaceuticals | Series C | 0 |
| 6/2022 | Yueer Gene | Series B | 0 |
| 10/2018 | Milestone Pharmaceuticals | Series D | 80M |
| 2/2023 | VFlow Tech | Series A | 0 |
| 11/2018 | Mirum Pharmaceuticals | Series A | 120M |
| 12/2020 | Reneo Pharmaceuticals | Series B | 0 |
| 6/2020 | 4D Molecular Therapeutics | Series C | 0 |
| 1/2022 | AvengeBio | Series A | 0 |
| 7/2020 | Cyclerion Therapeutics | Post-IPO Equity | 0 |
| 4/2022 | Us2.ai | Series A | 15M |
| 9/2021 | BioAtla | Post-IPO Equity | 0 |
| 8/2017 | Milestone Pharmaceuticals | Series C | 55M |
| 6/2022 | NuProbe | Series B | 0 |
| 5/2020 | Amplyx Pharmaceuticals | Series C | 0 |
| 3/2017 | Boragen | Series A | 10M |
| 6/2022 | Yueer Gene | Series B | 0 |
| 6/2022 | NuProbe | Series B | 0 |
| 4/2022 | Us2.ai | Series A | 0 |
| 2/2022 | Plexium | Series B | 0 |
| 1/2022 | AvengeBio | Series A | 0 |
| 9/2021 | BioAtla | Post-IPO Equity | 0 |
| 12/2020 | Reneo Pharmaceuticals | Series B | 0 |
| 7/2020 | Cyclerion Therapeutics | Post-IPO Equity | 0 |
| 7/2020 | BioAtla | Series D | 0 |
| 7/2020 | VelosBio | Series B | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
